SNRPD3 and mantle cell lymphoma: Orally available PRMT5 inhibitor (EPZ015666 [GSK3235025]) inhibits SmD3 methylation and RNA splicing as well as induces antitumor efficacy in mantle cell lymphoma (MCL) cells in vitro and in vivo (147).